Dr. Delmore is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10600 Quivira Rd. Suite 110
Sarah Cannon Cancer Institute at Overland Park Regional Medical Center
Overland Park, KS 66215Phone+1 913-541-5550Fax+1 913-541-5028
Summary
- I am a Board Certified Gynecologic Oncologist. I currently work at the Sarah Cannon Cancer Institute at Overland Park Regional Medical Center in Kansas City after 35 years in the Department of Obstetrics and Gynecology, UKSM-W. I retired as Emeritus Professor last year. I was not very good at retirement, and accepted a position at OPRMC on a part-time basis.
Education & Training
- University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 1983 - 1985
- University of Kansas (Wichita)Residency, Obstetrics and Gynecology, 1980 - 1983
- University of Kansas (Wichita)Residency, Obstetrics and Gynecology, 1979 - 1979
- Baylor College of MedicineClass of 1978
Certifications & Licensure
- KS State Medical License 1980 - 2025
- MO State Medical License 2020 - 2025
- TX State Medical License 1979 - 2025
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
- Fellow (FACS) American College of Surgeons
Publications & Presentations
PubMed
- 21 citationsRandomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian t...Robert L. Coleman, James Moon, Anil K. Sood, Wei Hu, James E. Delmore
European Journal of Cancer. 2014-06-01 - 47 citationsA phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancerDavid Bender, Michael W. Sill, Heather A. Lankes, Henry D. Reyes, Christopher J. Darus
Gynecologic Oncology. 2015-09-01 - 74 citationsPhase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an int...George A. Omura, Mark F. Brady, Katherine Y. Look, Hervy E. Averette, James E. Delmore
Journal of Clinical Oncology. 2003-08-01
Professional Memberships
- Member
- Member
- Society of Gynecologic OncologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: